Vivo Ventures Leads $30 Million Funding of Shanghai Jingfeng Pharma
November 05, 2012 at 09:50 AM EST
Vivo Ventures, the California-China healthcare venture capital company, is the lead investor in a 190 million RMB ($30 million) funding round for Shanghai Jingfeng Pharmaceutical Co., according to Venture Wire. In January, Vivo closed Vivo Ventures VII, a $375 million fund. It pledged to allocate 45% of that to China life science companies. Founded in 2003, Shanghai Jingfeng Pharma is GMP-certified by the SFDA to make sodium hyaluronate API. More details.... Share this with colleagues: var switchTo5x=true; stLight.options({publisher:'d7871f5b-67bc-4d30-b66f-1465d0b97213'});